INmune Bio, Inc.INMBNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
73.54%
↑ 217% above average
Average (36q)
-62.68%
Historical baseline
Range
High:122.68%
Low:-682.40%
Volatility
-1284.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 73.54% |
| Q2 2025 | -151.13% |
| Q1 2025 | -5.65% |
| Q4 2024 | 23.77% |
| Q3 2024 | -24.08% |
| Q2 2024 | 11.60% |
| Q1 2024 | -31.13% |
| Q4 2023 | 1.81% |
| Q3 2023 | -31.72% |
| Q2 2023 | 0.54% |
| Q1 2023 | -12.05% |
| Q4 2022 | 24.49% |
| Q3 2022 | -12.97% |
| Q2 2022 | 0.94% |
| Q1 2022 | 28.62% |
| Q4 2021 | -2.25% |
| Q3 2021 | -42.12% |
| Q2 2021 | -46.07% |
| Q1 2021 | -42.20% |
| Q4 2020 | 32.08% |
| Q3 2020 | -123.79% |
| Q2 2020 | -1.81% |
| Q1 2020 | 10.69% |
| Q4 2019 | 24.41% |
| Q3 2019 | -682.40% |
| Q2 2019 | 79.38% |
| Q1 2019 | -1.12% |
| Q4 2018 | -22.08% |
| Q3 2018 | 75.06% |
| Q2 2018 | -116.94% |
| Q1 2018 | -564.95% |
| Q4 2017 | -38.96% |
| Q3 2017 | -86.67% |
| Q2 2017 | -640.10% |
| Q1 2017 | 122.68% |
| Q4 2016 | -148.50% |
| Q3 2016 | 0.00% |